Biden promised to turn the page on Trump. Now he's being replaced by him
Firefighters prepare for increasing gusts following brief reprieve for LA area
John Ratcliffe, tapped by Trump to lead the CIA, will face questioning in the Senate
Nippon Steel wants to work with Trump administration on US Steel deal, Mori tells WSJ
After cable damage, Taiwan to step up surveillance of flag of convenience ships
BOJ will raise rates if economy, price conditions continue to improve, Ueda says
Manatees congregate in warm waters near power plants as US winter storms graze Florida
AAPI adults prioritize immigration, but split on mass deportations: AP-NORC/AAPI Data poll
As Los Angeles burns, Hollywood's Oscar season turns into a pledge drive
As fires ravage Los Angeles, Tiger Woods isn't sure what will happen with Riviera tournament
Antetokounmpo gets 50th career triple-double as Bucks win 130-115 to end Kings' 7-game win streak
TOKYO (Reuters) - Japanese drugmaker Eisai is developing a dementia treatment that it aims to commercialise in the U.S. by fiscal 2030, the Nikkei reported on Sunday.
The new drug targets a protein called tau, which causes symptoms of Alzheimer's disease, the newspaper reported.
Eisai already has a dementia drug on the U.S. market called Leqembi, co-developed with U.S. peer Biogen.
The companies announced on Friday that they would start Leqembi sales in China, making that country the third where the treatment is available after the U.S. and Japan.
(Reporting by Kevin Buckland; Editing by Christopher Cushing)
